A DNA tetrahedral drug complex for treating neovascular retinal diseases and its preparation method and use
By combining Bevasiranib with DNA tetrahedron to form a TDN-Bevasiranib complex, the problems of poor efficacy and side effects of existing VEGF inhibitors are solved, and more efficient VEGF silencing and angiogenesis inhibition effects are achieved.
CN115969988BActive Publication Date: 2025-09-19CHENGDU GENREZE GENE TECH CO LTD
5 Cites 0 Cited by
Patent Information
- Application Number
- CN202211066316.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-01
- Publication Date
- 2025-09-19
- Estimated Expiration
- 2042-09-01
AI Technical Summary
Technical Problem
Existing VEGF inhibitors have poor efficacy and potential side effects in treating neovascular retinal diseases, especially long-term use may lead to tissue atrophy and other side effects.
Method used
DNA tetrahedron drug complex is used to combine Bevasiranib with DNA tetrahedron (TDNs) to form a TDN-Bevasiranib complex to improve the cell entry efficiency of Bevasiranib and the VEGF protein silencing effect.
Benefits of technology
It significantly improved the in vitro cell entry efficiency and VEGF protein silencing effect of Bevasiranib, demonstrated excellent angiogenesis inhibition in in vivo animal models, improved fundus leakage, and had outstanding retinal repair effects.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides a DNA tetrahedron drug complex for treating neovascular retinal diseases. The complex is formed by TDNs carrying Bevasiranib. The complex exhibits excellent inhibitory effect on neovascularization and significantly improves fundus leakage, with a very prominent retinal repair effect.
Need to check novelty before this filing date? Find Prior Art